Top Page
Tian Ruixiang Holdings
(NASDAQ:TIRX)
Tian Ruixiang Holdings (TIRX) vs. SPDR S&P 500 ETF (SPY)
Tian Ruixiang Holdings Business Overview & Revenue Model
Tian Ruixiang Holdings Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.22M | 1.24M | 1.35M | 2.79M | 3.25M |
| Gross Profit | 1.52M | 783.46K | -1.34M | 1.84M | 2.51M |
| EBITDA | -2.80M | -2.94M | -4.74M | -2.00M | 787.68K |
| Net Income | -3.99M | -2.45M | -4.68M | -1.94M | 634.10K |
Balance Sheet | |||||
| Total Assets | 39.98M | 35.48M | 35.03M | 40.35M | 10.06M |
| Cash, Cash Equivalents and Short-Term Investments | 28.39M | 26.80M | 26.18M | 30.02M | 6.14M |
| Total Debt | 1.18M | 57.40K | 145.52K | 660.97K | 321.93K |
| Total Liabilities | 6.09M | 3.06M | 1.55M | 1.36M | 1.42M |
| Stockholders Equity | 33.89M | 32.42M | 33.48M | 38.99M | 8.64M |
Cash Flow | |||||
| Free Cash Flow | 897.89K | 994.30K | -201.11K | -1.37M | -51.63K |
| Operating Cash Flow | 897.89K | 994.30K | -198.76K | -1.36M | -48.17K |
| Investing Cash Flow | -1.82M | -992.72K | -28.90M | -7.50M | -3.46K |
| Financing Cash Flow | 1.19M | -283.00 | 0.00 | 32.64M | -478.25K |
Tian Ruixiang Holdings Technical Analysis
Tian Ruixiang Holdings Risk Analysis
Tian Ruixiang Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | 34.30M | 13.64 | -0.16% | ― | 19.30% | -17.56% | |
54 Neutral | 34.36M | 11.72 | 0.00% | ― | 80.80% | 0.00% | |
51 Neutral | 121.31M | -11.77 | 4.33% | ― | 16.19% | 89.75% | |
45 Neutral | 75.31M | -1.29 | -13.77% | ― | 17.46% | 60.17% | |
41 Neutral | $51.59M | ― | -11.18% | ― | 624.24% | 85.46% | |
38 Underperform | 3.39M | -0.26 | -302.66% | ― | 1.07% | 96.67% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
Tian Ruixiang Holdings Corporate Events
On August 28, 2025, Tian Ruixiang Holdings Ltd, a company based in Beijing, dismissed RBSM LLP as its independent registered public accounting firm. The company’s board of directors and audit committee approved the appointment of Enrome LLP as the new independent registered public accounting firm, effective September 12, 2025, for the fiscal year ending October 31, 2025.
Tian Ruixiang Holdings Ltd, a company based in Beijing, China, has announced the dismissal of its former independent registered public accounting firm, RBSM LLP, effective August 28, 2025. The decision was approved by the company’s board of directors and audit committee. RBSM’s reports on the company’s financial statements for the fiscal years ending October 31, 2023, and 2024 were unqualified, and there were no disagreements or reportable events during their tenure. The company has requested RBSM to provide a letter to the U.S. Securities and Exchange Commission confirming their agreement with the statements made by Tian Ruixiang Holdings Ltd.
On September 2, 2025, TIAN RUIXIANG Holdings Ltd announced a reverse stock split of its ordinary shares at a ratio of five to one, effective September 5, 2025. This move will adjust the par value of the company’s Class A and Class B ordinary shares from US$0.025 to US$0.125 per share. The shares will trade under the existing symbol ‘TIRX’ but with a new CUSIP number. This strategic financial restructuring is aimed at consolidating shares to potentially enhance market perception and trading liquidity, impacting stakeholders by altering share value and structure.
On August 26, 2025, Tian Ruixiang Holdings Ltd announced the resignation of Ms. Xu Sheng from her roles as Director, Chairman of the Board, and CEO due to personal reasons, with no disagreements with the company. The board expressed gratitude for her contributions. Mr. Xu Baohai has been appointed to fill these roles, bringing extensive experience from his previous positions, which is expected to provide valuable insights and strengthen the company’s leadership.
Tian Ruixiang Holdings Ltd has released its unaudited condensed consolidated financial statements for the six months ended April 30, 2025, showing a significant increase in net revenue to $2.8 million compared to $178,345 in the same period in 2024. Despite the revenue growth, the company reported increased operating expenses, leading to a comprehensive loss, which may impact its financial stability and investor confidence.
On August 18, 2025, Tian Ruixiang Holdings Ltd held an Extraordinary General Meeting of Shareholders in Beijing, where a resolution was adopted to consolidate the company’s shares. The consolidation involves converting every five Class A and Class B ordinary shares into one share of higher par value, effectively reducing the total number of shares while maintaining the same rights and restrictions. This decision, supported by 98.20% of the voting power, aims to streamline the company’s share structure and potentially enhance its market positioning.
Tian Ruixiang Holdings Ltd has announced an Extraordinary General Meeting of Shareholders to be held on August 18, 2025, in Beijing, China. The meeting will focus on approving a share consolidation where every five Class A and Class B ordinary shares will be consolidated into one share, effectively changing the par value of the shares. This move aims to streamline the company’s share structure and potentially enhance its market positioning. Shareholders are encouraged to vote on the proposal through various methods, including internet, email, mail, fax, or in person at the meeting.
On June 30, 2025, TIAN RUIXIANG Holdings Ltd completed its acquisition of Ucare Inc., marking a strategic expansion into AI-powered health insurance solutions. The acquisition, valued at $150 million, involves the issuance of 101,486,575 Class A ordinary shares and aims to leverage Ucare’s AI-driven platform to enhance TRX’s health insurance offerings. This move positions TRX at the intersection of healthcare and insurance, aiming to transform health insurance design and service delivery while expanding its reach into in-hospital distribution channels. The integration of Ucare’s generative AI platform is expected to streamline operations, reduce fraud, and improve pricing precision, ultimately creating a seamless insurance-hospital ecosystem.